ClinicalTrials.gg
RecruitingNCT07102823COPD-PHUpdated Jan 14, 2026

Clinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease

An observational study in Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension, sponsored by Medical University of Graz. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Medical University of Graz · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria — 14 open to participants now, 20 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Austria.

Planned enrollment
5th of 12
1,000 · median 877
Started
2025
with 4 others
Observational
13 of 96
4 open now
Primary completion
2026-12
later than 9 of 19 live
Registered
94th of 96
by date

Among the 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria, this one is the 5th largest by planned enrollment of the 12 observational ones that give a count, is one of 5 that started in 2025, is one of 13 observational ones, reaches primary completion later than 9 of the 19 other live ones, and was the 94th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria, or all of them as a file.
02

Study summary

Registry of COPD (Chronic Obstructive Pulmonary Disease) patients who underwent right heart catheterization (RHC) and full clinical evaluation for pulmonary hypertension

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Pulmonary Hypertension

Keywords

  • pulmonary hypertension
  • chronic obstructive pulmonary disease
  • right heart catheterization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

COPD patients who underwent RHC

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical diagnosis of
  • right heart catheterization including mPAP (Mean Pulmonary Artery Pressure), PVR (Pulmonary Vascular Resistance), PAWP (Pulmonary Artery Wedge Pressure), CO (cardiac output)
  • age >= 18 years

Exclusion criteria

Exclusion Criteria:

  • pediatric patients
  • no or no RHC
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Severe Pulmonary Hypertension (PH)

    pulmonary vascular resistance \> 5 WU (Wood Units)

    Time frame: at inclusion

  2. all-cause mortality

    all-cause mortality

    Time frame: Until 2026

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 5, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 31, 2027
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07102823
Responsible party
Sponsor
First posted
Aug 5, 2025
Start date
Sep 1, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 14, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion